The National Association of Boards of Pharmacy opposes FDA's plan to develop a new regulatory category for non-traditional drug compounding, adding to a growing chorus of stakeholders voicing problems the idea, and instead calls for a new “third-tier non-traditional manufacturer”category of facilities that would be allowed to prepare non-patient specific products -- an approach compounding pharmacists are also weighing but on which they have yet to take a formal position.
Subscription required to read full article